Company Description
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally.
The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products.
It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands.
The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products.
This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals.
Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
| Country | United States |
| IPO Date | Sep 18, 2019 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 12,800 |
| CEO | Paul A. Keel |
Contact Details
Address: 200 S. Kraemer Blvd., Bldg. E Brea, California 92821 United States | |
| Phone | 714-817-5418 |
| Website | envistaco.com |
Stock Details
| Ticker Symbol | NVST |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001757073 |
| CUSIP Number | 29415F104 |
| ISIN Number | US29415F1049 |
| Employer ID | 83-2206728 |
| SIC Code | 3843 |
Key Executives
| Name | Position |
|---|---|
| Amir Aghdaei | President, Chief Executive Officer and Director |
| Mark E. Nance | Senior Vice President, General Counsel and Secretary |
| Stephen Keller | Vice President of Investor Relations and Principal Financial Officer |
| Faez Kaabi | Vice President, Chief Accounting Officer and Corporate Controller |
| Andrew Chen | Chief Information Officer |
| Juan Arbona | Chief Compliance Officer |
| Mischa M. Reis | Senior Vice President of Strategy and Corporate Development |
| Suraj Satpathy | Chief Human Resources officer |
| Filippo Impieri | Senior Vice President of Emerging Markets |
| Claudia Ortiz | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 1, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 8, 2024 | ARS | Filing |
| Apr 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |